



Debatní sekce: Otázky kolem katetrizační ablace v různých indikacích

Predsieňové tachykardie po ablácii fibrilácie predsiení: ako ďalej ?

Peter Hlivák

OAKS NÚSCH a LF SZU,


Bratislava,



QRS : 102 ms
QT / QTcBaz : 380 / 412 ms
PR : - ms
P : 74 ms
RR / PP : 842 / 234 ms
P / QRS / T : 95 / -4 / 14 stupne

115/80

Technik:
Objed. lekár:
Odosiel. lekár:
Ošetr. lekár:



Atrial tachycardias after AF ablation

- "*common enough*" + *very symptomatic* → all operators performing AF ablation should be skilled in mapping and ablating
- incidence depending on various factors
 - predominant type of AF before index procedure
 - ablation strategy of the 1st procedure:
 - 2.6% (PVI alone) - 31% (linear lesions)
 - less after cryoballoon

Gerstenfeld EP, et al. Circulation 2004;110(11):1351-1357.
Chugh A, et al. J Am Coll Cardiol 2005;46(1):83-91.
Chugh A, et al. Heart Rhythm 2005;2(5):464-471.
Deisenhofer I, et al. Europace 2006;8(8):573-582.
Kuck KH, et al. N Engl J Med 2016;374(23):2235-2245.

Clinical considerations (of ATs post AF ablation)

- **Early onset after** the index **procedure**
 - inducibility immediately after PVI (16,3%) or more extensive ablation (38%)¹
 - > 80% ATs during first 2-4 weeks after AF ablation^{2,3}
- **Multiple different arrhythmias** in the same patient
- Most commonly **persistent** (78 - 92%)⁴
- Frequent and important **symptoms refractory** to management with rate-controlling drugs (more symptomatic than original AF)
- **Limited** effect of **antiarrhythmic drugs**
- **High recurrence** rate **after cardioversion**
- Often **requirement** of at least one **subsequent ablation** procedure

1. Daoud EG et al. *Journal of Cardiovascular Electrophysiology*, vol. 17, pp. 157-165, 2006.

2. Themistoclakis S et al. *Heart Rhythm*, vol. 5, no. 5, pp. 679-685, 2008.


3. Ouyang F et al. *Circulation*, vol. 111, pp. 127-135, 2005


4. Haissaguerre M et al. *Journal of Cardiovascular Electrophysiology*, vol. 16, pp. 1138-1147, 2005.

Atrial tachycardias

1. focal
2. small circuit ("microreentry")
3. macroreentry


Mechanism of ATs - „gap related“






Macroeentrant AFL: gap related

Macroeentrant AFL: gap related




Mechanism of ATs - „non-gap related“




Macroreentry AT

- 2 sites \geq 2 cm apart demonstrate entrainment with a PPI -tachycardia CL of 20 ms (i.e., within the circuit)
- **Typical AFL**
 - RA: CCW (common) and CW AFL (reverse common), lower-loop AFL, intraisthmus reentry
- **Atypical AFL**
 - prior atrial surgery or prior ablation for AF
 - RA: free wall reentry, upper-loop, crista terminalis, RA septum,
 - LA: type of circuit varies according to the nature of prior ablation and to the underlying structural heart disease
 - perimitral - or mitral isthmus-dependent or roof-dependent circuits
 - around regions of scar, double loop reentry


Atrial flutters after AF ablation




Atrial flutters after AF ablation




Atrial flutters after AF ablation



Atrial flutters after AF ablation



Atrial flutters after AF ablation



Determining the location of the reentry circuit: role of the 12-lead ECG

- more extensive scarring (more extensive LA ablation or spontaneous → more limited interpretation of the 12-lead ECG
- clear isoelectric line in all 12 leads → focal AT (“trully focal” or microreentry)
- Typical CTI -dependent AFL frequently atypical appearance after prior LA ablation

12-lead ECG: general rules




- Tachycardias arising near the PV ostia → inferior axis and positive F waves across the precordial leads
- "m"-shaped F-wave in lead V1 → left PV exit
- Right PV tachycardias → amplitude in lead II > III and a positive F wave in lead I
- Mitral annular flutter
 - similar appearance to left PV tachycardias
 - initial negative component in the precordial leads or amplitude in lead V2 less than that in V1 and V3 might be suggestive

AT from RSPV




Flutter waves amplitude in lead II > III and a positive F wave in lead I

Initial step: check the CS activation



- CTI-dependent flutter
- right PV tachycardia
- counterclockwise mitral annular flutter
- Left PV tachycardia
- clock-wise mitral flutter
- roof-dependent flutter


Mapping of ATs after AF ablation




Practical approach to treat ATs post Afib ablation

- To know the substrate and previous ablation strategy
 - PVI alone
 - PVI + lines
 - PVI + CFAEs...
- Check the PVs → **PVI is the must !** (both triggers and critical isthmus)
- Check the lines → **checking for bidirectional conduction block is the must!** (gaps, zone of slow conduction...)


EKG




Laso v LIPV a LSPV




Laso v LIPV



3D mapa L'P




LPV isolation



AT from LSPV



EKG







Mapping of ATs

- Activation mapping
- Entrainment mapping


Activation mapping


- conventional: sequentially
 - annotation manually or automated
- Multipoint mapping
- (Ultra) High-density and automated mapping systems (Rhythmia, Ripple mapping...)
 - true clinical value still unknown





Perimitrálny AFL






























Entrainment mapping

- **stable reentrant circuit** → better and more accurate approach to localize
- **"gold standard"** → more preferred for reentrant tachy
- fusion of the F wave difficult to interpret
- primary goal: identification of regions with a PPI within 20 ms of the tachycardia CL
- cave: pace at or near threshold !
- disadvantage: risk of termination or changing the tachycardia to different one or degeneration into Afib


Ablation strategy

- PV tachycardias: usually 2 gaps in previous PVI line are present
- Macroreentrant tachy: ablation to connect anatomic obstacles
 - mitral annular flutter:
 - MA and LIPV (mitral isthmus)
 - anterior line (MA and LSPV or RSPV or roof line)
 - often epicardial ablation within the CS is required (ca in 80% of pts)
 - endpoint of linear ablation: proof of bidirectional block using pacing maneuvers rather than tachycardia termination
- After termination of the clinical tachycardia → always re-isolation of any reconnected PVs !



Earliest (fractionated) activity




Earliest (fractionated) activity




How to prevent post Afib AFL ?




LA/RA Linear Lesions






Blok na mitrálnom istme







Roof block



Pac. D.I., 65-r. žena, CHADS2VASc 2, AHT




Pac. F.K, 63r. muž, AHT, st. RFA AD v
1995, CHA2DS2VASc: 1, EHRA III




Ablation of atypical atrial flutters using ultra high density-activation sequence mapping


LA anteroseptal flutter




Complex mitral isthmus flutter



Double loop LA flutter




Ongoing Management of Atrial Flutter



Thank you for your attention

hlivakp@gmail.com

Acute Treatment of Atrial Flutter



*Anticoagulation as per guideline is mandatory.


†For rhythms that break or recur spontaneously, synchronized cardioversion or rapid atrial pacing is not appropriate.

Non-Isthmus-Dependent Atrial Flutters: catheter ablation


Catheter ablation is useful in pts with recurrent symptomatic non-CTI-dependent AFL after failure of at least 1 antiarrhythmic agent (Class I)

- No prospective RCTs have compared the efficacy or safety of AAD with CA
- In general, CA of non-CTI-dependent AFL is more difficult than ablation of CTI-dep. AFL
 - anatomic circuits are complex, often not anatomically defined, difficult to locate.
 - Knowledge of the prior surgical or ablation approach and detailed activation and entrainment mapping of the tachycardia are useful during attempts at ablation
 - location of the circuit determines ablation approach and risks.
- CA is reasonable in patients with recurrent symptomatic non-CTI-dependent AFL as primary therapy, before therapeutic trials of antiarrhythmic drugs, after carefully weighing potential risks and benefits of treatment options (IIa)


CARTO and CT merge




Earliest (fractionated) activity



AT in LPVs continues...




Mechanisms of atrial flutter and atrial tachycardia



A: Isthmus-dependent reverse common (clockwise) atrial flutter. B: Isthmus-dependent common (counter clockwise) atrial flutter. C: Focal atrial tachycardia with circumferential spread of activation of the atria (can arise from multiple sites within the left and right atrium). D: Microreentrant atrial tachycardia with circumferential spread of activation of the atria. E: Perimitral atrial flutter. F: Roof-dependent atrial flutter.


LACA-WACA-PVI








- Encircling lesions
 - eliminate PV triggers
 - may also eliminate “rotors” or “mother waves”
 - 20-30% of LA is excluded limiting area for circulating wavelets - critical mass ?
- Why is there 20-30% recurrence of AF? (If the triggers for paroxysmal AF have been eliminated)
 - Reconnection of the pulmonary veins
 - Non pulmonary vein triggers (e.g. Ligament of Marshall, CS...)

Persistent Afib ablation approaches


- Bordeaux stepwise approach
- Hamburg approach...






Multielectrode ablation catheters



Electromagnetic (SmartTouch) vs fiber-optic (TactiCath Quartz) contact force catheters



Force parameters discriminators for segments with isolation vs gaps (EFFICAS I)




successful ablations

gaps

successful ablations

gaps

Association of Atrial Tissue Fibrosis Identified by Delayed Enhancement MRI and Atrial Fibrillation Catheter Ablation The DECAAF Study



No. at risk

Stage 4	24	15	11	10	7	6
Stage 3	80	56	47	41	19	12
Stage 2	107	79	74	58	26	15
Stage 1	49	47	43	33	13	4


Predictors of Success Following AF Ablation


- Predictors of a poorer outcome, at least in some studies, include
 - (1) non-PAF and particularly long-term persistent AF
 - (2) LV dysfunction
 - (3) sleep apnea and obesity
 - (4) increased LA size
 - (5) increased age
 - (6) hypertension
 - (7) LA fibrosis as detected by cardiac MRI


Prediktory neúspechu/horších výsledkov katéetrovej ablácie FP

1. iná ako paroxyzmálna FP (predovšetkým dlhodobou perzistujúca FP)
 2. syndróm spánkového apnoe
 3. obezita
 4. dilatácia ĽP
 5. vyšší vek
 6. hypertenzia
 7. fibróza ĽP detegovaná pomocou MRI
 8. nižšia EF ĽK
- **Systematický prehľad prediktorov rekurencií FP po katéetrovej ablácii (Balk EM et al. JCE 2010)**
 - **25 štúdií**
 - **17 z nich študovalo EFLK**
 - **veľmi málo pac. malo EFLK < 40%**
 - **4 štúdie: exklúzia pac. s EFLK < 45%**
 - **5 štúdií: EFLK prediktor**


AF ablation - PVI










Izolácia pľúcnych žíl




Kryo izolácia




LA merge






ICE


JS 2015




JS 2015




CARTO




Different possible evolutions of AF in relation to substrate remodelling and trigger density







A conceptual model of atrial fibrillation events in relationship to underlying substrate




Basic mechanisms underlying AF-related remodelling and therapy




Pac. M.O, 41r. muž, dlhodobo perzistentá
FP, CHA2DS2VASc: 1, EHRA III, EFLK 30%



The 1st-generation vs the 2nd - generation cryoballoon ablation catheters




Fire and ICE Trial




FIRE AND ICE Safety

End Point	Radiofrequency Group (N=376)	Cryoballoon Group (N=374)	P Value**
	<i>no. of patients (%)</i>		
Primary safety end point†	51 (12.8)‡	40 (10.2)‡	
Death from any cause§	0	2 (0.5)¶	0.50
Stroke or TIA from any cause§	2 (0.5)	2 (0.5)	1.00
Atrial arrhythmia§	13 (3.5)	8 (2.1)	0.38
Atrial flutter or atrial tachycardia	10 (2.7)	3 (0.8)	0.09
Non-arrhythmia-related serious adverse events§	36 (9.6)	28 (7.5)	0.36
Groin-site complication**	16 (4.3)	7 (1.9)	0.09
Unresolved phrenic nerve injury††			
At discharge	0	10 (2.7)	0.001
At 3 months	0	2 (0.5)	0.25
At >12 months	0	1 (0.3)	0.50
Cardiac tamponade or pericardial effusion	5 (1.3)	1 (0.3)	0.22
Pulmonary or bronchial complication	4 (1.1)	2 (0.5)	0.69
Transient neurologic complication	3 (0.8)	1 (0.3)	0.62
Dyspnea	2 (0.5)	1 (0.3)	1.00
Gastrointestinal complication	2 (0.5)	1 (0.3)	1.00
Other, nonarrhythmia cardiac complications‡‡	0	3 (0.8)	0.12
Anxiety	0	1 (0.3)	0.50
Contrast media reaction	1 (0.3)	0	1.00
Contusion	1 (0.3)	0	1.00
Esophageal ulcer	0	1 (0.3)	0.50
Hematuria	1 (0.3)	0	1.00
Local edema	1 (0.3)	0	1.00
Atrioesophageal fistula	0	0	—
Pulmonary vein stenosis	0	0	—


Electromagnetic (SmartTouch) vs fiber-optic (TactiCath Quartz) contact force catheters




Contact Force




Technological Advances
Improved outcomes
Improved sustainability
Improved safety




Force parameters discriminators for segments with isolation vs gaps (EFFICAS I)




The electrocardiographic imaging (ECGI) procedure



The phase maps of ≥ 1000 -ms-long AF window show reentry events visualized intermittently in the right and left atria with their prephase electrograms on the right.



Evaluation of pulmonary veins during the 2nd procedure








- 158 PVs reevaluated at median of 6.0 months after the initial procedure.
- In total, reconnections detected in 39 PVs (24.7%) among 25 pts (62.5%).

Reconnections vs Recurrence

N	Recurrence (-)	Recurrence (+)	P value
	15	25	
Period from initial procedure (months)	7.0 [5.0-9.0]	6.0 [3.5-9.0]	.314
No. of reconnected PVs			
Total	14/60 (23.3%)	25/98 (25.5%)	.758
LSPV	4/15 (26.7%)	2/23 (8.7%)	.138
LIPV	2/15 (13.3%)	5/23 (21.7%)	.513
RSPV	2/15 (13.3%)	3/25 (12.0%)	.902
RIPV	6/15 (40.0%)	14/25 (56.0%)	.327
LCPV		1/2 (50.0%)	

- No significant difference between those with and those without clinical recurrences with regard to:
 - clinical characteristics, procedural results, incidence of reconnections (25/98 vs 14/60, $p = .758$)
- The most common gap: RIPV bottom in both groups
- Non-PV foci (with AF initiation) identified in 10 of 25 patients with clinical recurrences (during 2nd procedure)

One-size-fits-all?



BARTOS Camera
656330209
Apr 09 9:44
M
02 Jul 2015
08:08:03

mA:500
mm:300
mAs:170
kVp:100
Tm:0.5mm
Rad:0.016
LAC165 CRA27